-
Domestic innovative drugs are ushering in the development stage of "big waves and sandstorms", and pharmaceutical companies continue to increase their construction efforts
Time of Update: 2022-05-14
As a pharmaceutical company driven by innovation and R&D, Simcere Pharma stated in its 2021 financial report that Simcere China has listed 5 innovative drugs with differentiated value, and the sales revenue of innovative drugs in 2021 will account for 62.
-
In 2022, domestic and foreign pharmaceutical companies are setting off a "wave of layoffs"
Time of Update: 2022-05-14
In recent years, with the increasing competition in the pharmaceutical market, domestic and foreign pharmaceutical companies have begun to use strategic restructuring to improve efficiency and reduce costs, such as cutting pipelines, reducing teams, and restructuring .
-
BeiGene's CD3/CD19 Dual Antibody Belintoumumab New Indication Approved
Time of Update: 2022-05-14
Article source: Medical Cube InfoAuthor: infoOn April 29, BeiGene's new indication of belintoumumab for injection submitted by BeiGene was approved by the State Food and Drug Administration for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adults and children .
-
Medical device companies have announced their first quarterly reports, and many companies' net profit has risen sharply
Time of Update: 2022-05-14
According to data, from 2014 to 2020, China's medical device market has achieved a growth of 500 billion yuan .
18%; the net profit attributable to shareholders of listed companies is 8 billion yuan, a year-on-year increase of 20.
-
FDA clears Pfizer's DMD gene therapy phase 3 clinical trial is about to restart
Time of Update: 2022-05-14
S. Food and Drug Administration (FDA) has notified the company that the Phase 3 clinical trial of its gene therapy fordadistrogene movaparvovec for the treatment of Duchenne muscular dystrophy (DMD) will continue .
-
Drug withdrawal from the Internet has become the norm, and hundreds of drugs have been disqualified from the Internet
Time of Update: 2022-05-14
The content of the notice shows that 123 drugs from 54 companies have recently submitted applications for withdrawal due to production line transformation, rising costs, shortage of raw materials, and suspension of production, which cannot guarantee the normal supply of medical institutions in our province .
-
National Health Commission: During the "14th Five-Year Plan" period, the construction of key clinical specialties will be accelerated to improve the level of medical technology
Time of Update: 2022-05-14
The state will also support innovations in key technical fields such as regenerative medicine, precision medicine, brain science, and biomedicine, strive to solve a number of "stuck neck" technologies, and promote relevant specialist capabilities to enter the international forefront .
-
With the intensification of pharmaceutical reform, the gross profit margin of a large number of biopharmaceutical companies has declined
Time of Update: 2022-05-14
As of April 27, statistics show that among the listed companies in the pharmaceutical and biological industry that have disclosed their annual reports on A-shares and H-shares, a total of 44 companies will have revenue of more than 10 billion yuan in 2021 .
-
What is the intention of pharmaceutical companies to hold a group while losing weight?
Time of Update: 2022-05-14
For example, some time ago, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and sign a contract with Fujian Shencheng "Letter of Intent for Equity Transfer" .
-
Under the centralized procurement, this track may become a "new battlefield" for Chinese patent medicine!
Time of Update: 2022-05-14
com, it is estimated that the sales volume of Chinese patent medicines in urban physical pharmacies and online pharmacies in China will be close to 120 billion yuan in 2021, a year-on-year increase of 5.
-
In 2022, the enthusiasm for innovation and research and development of pharmaceutical companies will remain undiminished, and cooperation will become a trend
Time of Update: 2022-05-14
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system .
-
Jiangxi Provincial Medical Insurance Bureau announced the results of 290 countries talking about drug classification management
Time of Update: 2022-05-14
The two channels of inpatient and outpatient services in dual-channel medical institutions have been opened up, and the insured people will be included in the scope of the overall fund payment when they use the negotiated drugs of Class A and Class B in the hospital or outpatient clinic, and the current treatment policies remain the same .
-
8 pharmaceutical companies, and the number of generic drugs that have been reviewed has exceeded 50!
Time of Update: 2022-05-14
According to incomplete statistics in the industry, as of April 22, a total of 98 varieties (182 specifications) of Qilu Pharmaceutical have passed/deemed to have passed the evaluation, of which 43 were the first to pass the evaluation, including gefitinib tablets, olanzapine orally disintegrating Tablets, Emtricitabine Capsules, etc.
-
There is a large unmet clinical demand for rare disease drugs, and multinational pharmaceutical companies continue to enter the market
Time of Update: 2022-05-14
Bristol-Myers Squibb, as an early multinational pharmaceutical company in the field of rare diseases, has also made continuous efforts in the research and development of rare diseases in recent years .
-
After artificial joints, the market for orthopedic spinal medical consumables is about to be reshuffled!
Time of Update: 2022-05-14
A few days ago, the "Notice on Carrying out the Historical Purchase Data of Orthopaedic Spine Medical Consumables" issued by the Joint Procurement Office of High Value Medical Consumables of the State Organization shows that in order to do a good job in the centralized procurement of orthopaedic spinal medical consumables, find out the actual situation.
-
15 days of fast supply!
Time of Update: 2022-05-14
Innovation leads development, and the holding of the first launch ceremony of Tigolasheng marked the official transformation of this high-tech achievement into clinical use, benefiting the majority of patients, and also taking a solid step for Luoxin Pharmaceutical to accelerate the development of scientific and technological innovation .
-
20 medical institutions in this place plan to be included in medical insurance, who are all?
Time of Update: 2022-05-14
The content of the "Announcement on the List of Medical Institutions to be Included in the Management of Medical Insurance Agreements" shows that in accordance with the "Administrative Measures for the Designated Medical Insurance of Medical Institutions in Tianjin" (Jin Yi Bao Gui Zi [2021] No.
-
The disclosure of the annual report and the first quarterly report of the pharmaceutical industry is completed, and CXO is still the focus of the industry allocation
Time of Update: 2022-05-14
In the medium and long term, according to industry prosperity indicators such as investment and financing activity in the primary market and corporate R&D expenditure, with the rise of some innovative drugs and emerging therapies, the related CXO business has brought considerable incremental market to the industry.
-
The overall performance of the traditional Chinese medicine sector achieved high growth and ushered in greater investment opportunities
Time of Update: 2022-05-14
Among them, the overall performance of the traditional Chinese medicine sector has also achieved high growth, with 30 traditional Chinese medicine companies having a net profit of more than 100 million yuan .
-
Omicron Variant New Coronavirus Inactivated Vaccine Approved to Enter Clinical Trials
Time of Update: 2022-05-14
Yang Xiaoming, chief engineer of Sinopharm Group and chairman of Sino Bio, introduced that according to the guidelines and research and development strategies of the improved new crown vaccine of the State Food and Drug Administration, since December 9, 2021, the research and development of the new coronavirus inactivated vaccine of the Omicron variant strain has been launched.
